Dr Reddy's Laboratories, an integrated global pharmaceutical company, on Tuesday announced the launch of Vigabatrin Tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril (vigabatrin) Tablets, USP, approved by the U.S. Food and Drug Administration (USFDA). 

Vigabatrin Tablets USP are available in 500 mg tablets in a bottle count size of 100.

"We are pleased that this product has been designated as a Competitive Generic Therapy (CGT) by the FDA," said Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "With a CGT designation, we have 180-day CGT exclusivity to market this product."

The Sabril brand and generic had U.S. sales of approximately USD 141 million MAT for the most recent twelve months ending in December 2020 according to IMS Health.

Shares of the company gained Rs 94.1, or 2.12%, to trade at  Rs 4,522.70.  The total volume of shares traded  was  83,871 at the BSE (1.09 p.m., Tuesday).